dc.contributor.author |
Cappellini M.D. |
dc.contributor.author |
Motta I. |
dc.contributor.author |
Musallam K.M. |
dc.contributor.author |
Taher A.T. |
dc.contributor.editor |
Vichinsky E.P.Neufeld E.J. |
dc.date |
Aug-2010 |
dc.date.accessioned |
2017-10-05T15:37:53Z |
dc.date.available |
2017-10-05T15:37:53Z |
dc.date.issued |
2010 |
dc.identifier |
10.1111/j.1749-6632.2010.05548.x |
dc.identifier.isbn |
9.7815733178e+012 |
dc.identifier.issn |
00778923 |
dc.identifier.uri |
http://hdl.handle.net/10938/16006 |
dc.description.abstract |
As the life expectancy of β-thalassemia patients has markedly improved over the last decade, several new complications are being recognized. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia patients, has led to the identification of a hypercoagulable state in thalassemia. In this review, the molecular and cellular mechanisms leading to hypercoagulability in thalassemia are highlighted, and the current clinical experience is summarized. Recommendations for thrombosis prophylaxis are also discussed. © 2010 New York Academy of Sciences. |
dc.format.extent |
|
dc.format.extent |
Pages: (231-236) |
dc.language |
English |
dc.publisher |
OXFORD |
dc.relation.ispartof |
Publication Name: Annals of the New York Academy of Sciences; Publication Year: 2010; Volume: 1202; Pages: (231-236); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Redefining thalassemia as a hypercoagulable state |
dc.type |
Conference Paper |
dc.contributor.affiliation |
Cappellini, M.D., Universitá di Milano, Policlinico Foundation IRCCS, Milan, Italy |
dc.contributor.affiliation |
Motta, I., Universitá di Milano, Policlinico Foundation IRCCS, Milan, Italy |
dc.contributor.affiliation |
Musallam, K.M., Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.affiliation |
Taher, A.T., Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon |
dc.contributor.authorAddress |
Cappellini, M. D.; Universitá di Milano, Fondazione Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena IRCCS, Milan, Italy; email: maria.cappellini@unimi.it |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
Hematology-Oncology |
dc.contributor.authorEmail |
maria.cappellini@unimi.it |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Cappellini, MD |
dc.contributor.authorInitials |
Motta, I |
dc.contributor.authorInitials |
Musallam, KM |
dc.contributor.authorInitials |
Taher, AT |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Cappellini, MD (reprint author), Univ Milan, Fdn Osped Maggiore Policlin Mangiagalli Regina El, Milan, Italy. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Ataga KI, 2007, BRIT J HAEMATOL, V139, P3, DOI 10.1111-j.1365-2141.2007.06740.x; Atichartakarn V, 2002, BRIT J HAEMATOL, V118, P893, DOI 10.1046-j.1365-2141.2002.03711.x; Atichartakarn V, 2003, INT J HEMATOL, V77, P299, DOI 10.1007-BF02983790; BORENSTAINBENYASHAR V, 1993, AM J HEMATOL, V44, P63; Pignatti CB, 1998, ACTA HAEMATOL-BASEL, V99, P76; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Butthep P, 1997, SE ASIAN J TROP MED, V28, p141A; BUTTHEP P, 1995, THROMB HAEMOSTASIS, V74, P1045; Butthep P, 2002, AM J HEMATOL, V70, P100, DOI 10.1002-ajh.10101; Cappellini MD, 2005, ANN NY ACAD SCI, V1054, P317, DOI 10.1196-annals.1345.039; Cappellini MD, 2000, BRIT J HAEMATOL, V111, P467, DOI 10.1046-j.1365-2141.2000.02376.x; CARLOS TM, 1994, BLOOD, V84, P2068; Chen SQ, 1996, AM J PHYSIOL-HEART C, V270, pH1951; DELPRINCIPE D, 1993, BRIT J HAEMATOL, V84, P111; ELDOR A, 1991, BLOOD, V77, P1749; ELDOR A, 1989, AM J HEMATOL, V32, P94, DOI 10.1002-ajh.2830320204; Gillis S, 1999, HAEMATOLOGICA, V84, P959; Giordano P, 1998, BRIT J HAEMATOL, V102, P903, DOI 10.1046-j.1365-2141.1998.00853.x; Habib A, 2008, HAEMATOL-HEMATOL J, V93, P941, DOI 10.3324-haematol.12460; Helley D, 1996, THROMB HAEMOSTASIS, V76, P322; HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111-j.1365-2141.1978.tb03662.x; Hovav T, 1999, BRIT J HAEMATOL, V106, P178; Iolascon A, 2001, HAEMATOLOGICA, V86, P1112; Karimi M, 2005, J PEDIAT HEMATOL ONC, V27, P380, DOI 10.1097-01.mph.0000174386.13109.28; Kuypers FA, 2004, CELL MOL BIOL, V50, P147; LOGOTHET.J, 1972, NEUROLOGY, V22, P294; Manfre L, 1999, AM J ROENTGENOL, V173, P1477; Manning JT, 1998, HUM NATURE-INT BIOS, V9, P53, DOI 10.1007-s12110-998-1011-4; MICHAELI J, 1992, ACTA HAEMATOL-BASEL, V87, P71; Ruf A, 1997, BRIT J HAEMATOL, V98, P51, DOI 10.1046-j.1365-2141.1997.1502965.x; Rund D, 2005, NEW ENGL J MED, V353, P1135, DOI 10.1056-NEJMra050436; SHINAR E, 1989, J CLIN INVEST, V83, P404, DOI 10.1172-JCI113898; SONAKUL D, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P516; SUMIYOSHI A, 1992, J TROP MED PUBLIC S2, V23, P29; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160-TH06-05-0267; Taher A, 2006, BLOOD CELL MOL DIS, V37, P12, DOI 10.1016-j.bcmd.2006.04.005; Taher AT, 2008, BLOOD REV, V22, P283, DOI 10.1016-j.blre.2008.04.001; Taher AT, 2010, J THROMB HAEMOST, V8, P54, DOI 10.1111-j.1538-7836.2009.03651.x; Tavazzi D, 2001, BRIT J HAEMATOL, V112, P48, DOI 10.1046-j.1365-2141.2001.02482.x; Tripodi A, 2009, HAEMATOL-HEMATOL J, V94, P1520, DOI 10.3324-haematol.2009.010546; VANTEUNENBROEK A, 1989, NETH J MED, V35, P123; Weatherall DJ, 2001, THALASSAEMIA SYNDROM; WINICHAGOON P, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P556; Zalloua PA, 2003, THROMB HAEMOSTASIS, V89, P767; ZURLO MG, 1989, LANCET, V2, P27 |
dc.description.citedCount |
31 |
dc.description.citedTotWOSCount |
29 |
dc.description.citedWOSCount |
29 |
dc.format.extentCount |
6 |
dc.identifier.articleNo |
|
dc.identifier.coden |
ANYAA |
dc.identifier.pubmedID |
20712798 |
dc.identifier.scopusID |
77955894491 |
dc.identifier.url |
|
dc.publisher.address |
9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
New York Acad Sci |
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Ann.NY Acad.Sci. |
dc.relation.ispartOfIssue |
|
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Annals of the New York Academy of Sciences |
dc.relation.ispartofPubTitleAbbr |
Ann. New York Acad. Sci. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
1202 |
dc.source.ID |
WOS:000283099600035 |
dc.type.publication |
Series |
dc.subject.otherAuthKeyword |
hypercoagulability |
dc.subject.otherAuthKeyword |
stroke |
dc.subject.otherAuthKeyword |
thalassemia |
dc.subject.otherAuthKeyword |
thromboembolism |
dc.subject.otherChemCAS |
5 aza 2' deoxycytidine, 2353-33-5 |
dc.subject.otherChemCAS |
endothelial leukocyte adhesion molecule 1, 128875-25-2 |
dc.subject.otherChemCAS |
hemoglobin F, 9034-63-3 |
dc.subject.otherChemCAS |
hydroxyurea, 127-07-1 |
dc.subject.otherChemCAS |
intercellular adhesion molecule 1, 126547-89-5 |
dc.subject.otherChemCAS |
nitric oxide, 10102-43-9 |
dc.subject.otherChemCAS |
prostacyclin, 35121-78-9, 61849-14-7 |
dc.subject.otherChemCAS |
spectrin, 12634-43-4 |
dc.subject.otherChemCAS |
thromboxane A2, 57576-52-0 |
dc.subject.otherChemCAS |
von Willebrand factor, 109319-16-6 |
dc.subject.otherIndex |
5 aza 2' deoxycytidine |
dc.subject.otherIndex |
ankyrin |
dc.subject.otherIndex |
CD63 antigen |
dc.subject.otherIndex |
endothelial leukocyte adhesion molecule 1 |
dc.subject.otherIndex |
erythrocyte band 3 protein |
dc.subject.otherIndex |
hemoglobin F |
dc.subject.otherIndex |
hydroxyurea |
dc.subject.otherIndex |
intercellular adhesion molecule 1 |
dc.subject.otherIndex |
nitric oxide |
dc.subject.otherIndex |
PADGEM protein |
dc.subject.otherIndex |
prostacyclin |
dc.subject.otherIndex |
spectrin |
dc.subject.otherIndex |
thromboxane A2 |
dc.subject.otherIndex |
vascular cell adhesion molecule 1 |
dc.subject.otherIndex |
von Willebrand factor |
dc.subject.otherIndex |
beta thalassemia |
dc.subject.otherIndex |
blood transfusion |
dc.subject.otherIndex |
conference paper |
dc.subject.otherIndex |
erythrocyte |
dc.subject.otherIndex |
follow up |
dc.subject.otherIndex |
hemolysis |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
hypercoagulability |
dc.subject.otherIndex |
sickle cell anemia |
dc.subject.otherIndex |
splenectomy |
dc.subject.otherIndex |
thrombocyte |
dc.subject.otherIndex |
thrombocyte activation |
dc.subject.otherIndex |
thrombocyte aggregation |
dc.subject.otherIndex |
thrombocyte lifespan |
dc.subject.otherIndex |
thromboembolism |
dc.subject.otherIndex |
thrombosis |
dc.subject.otherIndex |
urinary excretion |
dc.subject.otherIndex |
Erythrocytes |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Splenectomy |
dc.subject.otherIndex |
Thalassemia |
dc.subject.otherIndex |
Thrombophilia |
dc.subject.otherKeywordPlus |
VIVO PLATELET ACTIVATION |
dc.subject.otherKeywordPlus |
RED-BLOOD-CELLS |
dc.subject.otherKeywordPlus |
BETA-THALASSEMIA |
dc.subject.otherKeywordPlus |
THROMBOEMBOLIC EVENTS |
dc.subject.otherKeywordPlus |
INTERMEDIA PATIENTS |
dc.subject.otherKeywordPlus |
ENDOTHELIAL-CELLS |
dc.subject.otherKeywordPlus |
MAJOR PATIENTS |
dc.subject.otherKeywordPlus |
COMPLICATIONS |
dc.subject.otherKeywordPlus |
ERYTHROCYTES |
dc.subject.otherKeywordPlus |
SURVIVAL |
dc.subject.otherWOS |
Hematology |
dc.subject.otherWOS |
Multidisciplinary Sciences |